Characteristic | All n = 66 | Adeno-NEPC n = 20 | Adeno-PCa n = 46 | P |
---|---|---|---|---|
Age (years) | 67.86 ± 7.05 | 68.65 ± 7.23 | 67.52 ± 7.02 | 0.837 |
Prostatectomy | Â | Â | Â | 0.308 |
 No | 27 (40.9%) | 11 (55.0%) | 16 (34.8%) |  |
 Yes | 39 (59.1%) | 9 (45.0%) | 30 (65.2%) |  |
Primary ADT | Â | Â | Â | 0.308 |
 No | 39 (59.1%) | 9 (45.0%) | 30 (65.2%) |  |
 Yes | 27 (40.9%) | 11 (55.0%) | 16 (34.8%) |  |
T staging | Â | Â | Â | 0.982 |
 T1 | 1 (1.5%) | 0 (0.00%) | 1 (2.2%) |  |
 T2 | 13 (19.7%) | 3 (15.0%) | 10 (21.7%) |  |
 T3 | 41 (62.1%) | 14 (70.0%) | 27 (58.7%) |  |
 T4 | 11 (16.7%) | 3 (15.0%) | 8 (17.4%) |  |
N staging | Â | Â | Â | 0.490 |
 N0 | 37 (56.1%) | 9 (45.0%) | 28 (60.9%) |  |
 N1 | 29 (43.9%) | 11 (55.0%) | 18 (39.1%) |  |
M staging | Â | Â | Â | 0.751 |
 M0 | 44 (66.7%) | 12 (60.0%) | 32 (69.6%) |  |
 M1 | 22 (33.3%) | 8 (40.0%) | 14 (30.4%) |  |
Gleason score | Â | Â | Â | 0.168 |
 < 7 | 1 (1.5%) | 0 (0.00%) | 1 (2.2%) |  |
 7 | 24 (36.4%) | 3 (15.0%) | 21 (45.6%) |  |
 > 7 | 41 (62.1%) | 17 (85.0%) | 24 (52.2%) |  |
PSA (ng/L) | Â | Â | Â | 0.177 |
 < 10 | 9 (13.6%) | 1 (5.0%) | 8 (17.4%) |  |
 10–20 | 12 (18.2%) | 1 (5.0%) | 11 (23.9%) |  |
 > 20 | 45 (68.2%) | 18 (90.0%) | 27 (58.7%) |  |
LDH (U/L) | Â | Â | Â | 0.207 |
 < 250 | 57 (86.4%) | 15 (75.0%) | 42 (91.3%) |  |
 ≥ 250 | 9 (13.6%) | 5 (25.0%) | 4 (8.7%) |  |
ALP (U/L) | Â | Â | Â | 0.894 |
 < 125 | 58 (87.9%) | 17 (85.0%) | 41 (89.1%) |  |
 ≥ 125 | 8 (12.1%) | 3 (15.0%) | 5 (10.9%) |  |